Theraclion SA

As of December 31, 2025, Theraclion SA carries a market capitalization of 36.70M, placing it among publicly traded companies globally. Its enterprise value stands at 38.26M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Theraclion SA's next confirmed earnings release is scheduled for April 29, 2027.

As of December 31, 2025, Theraclion SA has 60.96M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Theraclion SA maintains a current ratio of 2.55, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 23, 2026, Theraclion SA's stock has declined approximately 7.26% over the past 52 weeks. The 50-day moving average sits at 0.66, while the 200-day moving average is 0.62.

As of December 31, 2025, Theraclion SA holds 3.38M in cash and equivalents against 4.94M in total debt, resulting in a net debt position of 3.06M. Total book value stands at -2.59M, with working capital of 6.53M providing operational flexibility.

Theraclion SA's most recent stock split took place on July 26, 2016 with a 350:367 split ratio.